Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... 20, 2014 Earle Martin ... announced today that Ellen Teplitzky, an experienced attorney ... the pharmaceutical industry, has joined the firm as ... legal services practice. NDA Partners provides legal ... and testimony, to top law firms and their ...
(Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
(Date:10/19/2014)... 2014 The Asian Automatic patient billing ... analysis and forecast of revenue. The Automatic patient billing ... $463.9 million by 2018, at a developing CAGR of ... TOC of the Asian Automatic patient billing market, to ... also provides a glimpse of the segmentation of this ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , , , ... be key regulators of lipid, glucose and overall energy metabolism. Bile acid ... energy expenditure in muscle and brown fat, thereby conferring resistance to weight ... Metabolism (Vol. 10, Issue 3, Sept. 2, 2009) elaborates on a ...
... , ST. LOUIS, Sept. 1 Express Scripts, ... following investor conferences in September: , , Thomas Weisel Partners ... Four Seasons Hotel in Boston, MA. , , Morgan Stanley ... Grand Hyatt Hotel in New York, NY. , , These ...
... PHILADELPHIA, Sept. 1 ERT (Nasdaq: ERES ), announced ... Keith Schneck, the Company,s Executive Vice President and CFO, are scheduled to ... on September 9, 2009 in New York City, New York. , ... Company,s corporate website at http://www.ert.com . The webcast may ...
Cached Biology Technology:Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 2Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 3Express Scripts to Present at Investor Conferences 2ERT to Present at Baird's 2009 Health Care Conference on September 9, 2009 2
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... of the Walter and Eliza Hall Institute of Medical ... of the 2009 Pearl Meister Greengard Prize. ... the accomplishments of outstanding female scientists, at The Rockefeller ... prize was founded by Rockefeller Nobel laureate Paul Greengard ...
... highlands split and the Great Rift Valley formed, the ... different atmospheric circulation patterns than it does today, according ... central African nation. Neil J. Tabor, associate professor ... and an expert in sedimentology and isotope geochemistry, calculated ...
... over could benefit from new software* created at the National ... scientists has found a way to improve the efficiency of ... Alabama at Birmingham (UAB). Pneumonia is the world,s leading ... and poses a serious risk to elderly adults. The leading ...
Cached Biology News:Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize 2Ethiopia's climate 27 million years ago had higher rainfall, warmer soil 2Scientists create NICE solution to pneumonia vaccine testing problems 2
... suspension array system, 100-240 V, uses xMAP ... to 100 proteins and peptides in one ... of up to 100 color-coded bead sets, ... a unique reactant (enzyme substrates, receptors, antigens, ...
... The high-throughput fluidics (HTF) system, 100-240 V, ... suspension array system that automates delivery of ... into the Bio-Plex array reader. The HTF ... nonpressurized bulk sheath container to constantly maintain ...
... PYREX Delong style shaker flasks have three ... agitation of solutions to improve oxygen or ... reciprocating shakers. The long neck reduces splashing ... Their uniform wall thickness provides the proper ...
... gradient system uses two Adept CE 4100 ... CE 4200 dual wavelength detector for added flexibility. ... by PowerStream data processing software and interface unit, ... The supplied analytical pumps may be substituted ...
Biology Products: